Tonix Pharmaceuticals Holding Corp. is a specialty pharmaceutical company focused on developing new pharmaceutical products for CNS conditions. The Company develops therapies for disorders that include fibromyalgia syndrome and post-traumatic stress disorder. Its lead product candidates include TNX-102, for the management of fibromyalgia syndrome and TNX-105 to treat symptoms of post-traumatic stress disorder. Tonix Pharmaceuticals Holding Corp. is headquartered in New York.
| Revenue (Most Recent Fiscal Year) | $10.09M |
| Net Income (Most Recent Fiscal Year) | $-130.04M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 28.69 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 1.41 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -828.22% |
| Net Margin (Trailing 12 Months) | -828.22% |
| Return on Equity (Trailing 12 Months) | -57.93% |
| Return on Assets (Trailing 12 Months) | -51.04% |
| Current Ratio (Most Recent Fiscal Quarter) | 7.53 |
| Quick Ratio (Most Recent Fiscal Quarter) | 7.22 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | 0.91 |
| Book Value per Share (Most Recent Fiscal Quarter) | $19.17 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-3.86 |
| Earnings per Share (Most Recent Fiscal Year) | $-176.60 |
| Diluted Earnings per Share (Trailing 12 Months) | $-39.47 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 8.77M |
| Free Float | 8.76M |
| Market Capitalization | $282.09M |
| Average Volume (Last 20 Days) | 2.05M |
| Beta (Past 60 Months) | 1.70 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.03% |
| Percentage Held By Institutions (Latest 13F Reports) | 82.26% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |